| [1] |
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med,2012,366(10):883-892.
|
| [2] |
Almendro V, Marusyk A,Polyak K. Cellular heterogeneity and molecular evolution in cancer[J]. Annu Rev Pathol,2013,8:277-302.
|
| [3] |
杨壹羚, 范宇, 郎荣刚, 等. 乳腺癌HER2 基因遗传异质性与其临床病理特征的相关性研究[J]. 中华医学遗传学杂志,2010,27 (5):540-545.
|
| [4] |
Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics[J]. Proc Natl Acad Sci U S A, 2013, 110(10):4009-4014.
|
| [5] |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J].Arch Pathol Lab Med,2014,138(2):241-256.
|
| [6] |
Xia L, Wang L, Chung AS, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation[J]. J Biol Chem,2002,277(34):30716-30723.
|
| [7] |
Kreso A, O’brien CA, van Galen P, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer[J]. Science,2013,339(6119):543-548.
|
| [8] |
Shackleton M,Quintana E,Fearon ER,et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution[J]. Cell,2009,138(5):822-829.
|
| [9] |
杨壹羚, 褚嘉祐, 王明荣. 肿瘤遗传异质性[J]. 遗传,2013,35(1):1-9.
|
| [10] |
Weigelt B, Reis-Filho JS. Back to the basis: breast cancer heterogeneity from an etiological perspective[J]. J Natl Cancer Inst,2014 Aug 12,106(8).
|
| [11] |
Martins FC, De S, Almendro V, et al. Evolutionary pathways in BRCA1-associated breast tumors[J]. Cancer Discov,2012,2(6):503-511.
|
| [12] |
Couch FJ, Nathanson KL, Offit K. Two decades after BRCA:setting paradigms in personalized cancer care and prevention[J]. Science,2014,343(6178):1466-1470.
|
| [13] |
Yang MJ, Chiu HH, Wang HM, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method[J]. Ann Surg Oncol, 2010, 17(2):624-633.
|
| [14] |
Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer[J]. Nat Med,2014,20(8):897-903.
|
| [15] |
Battich N, Stoeger T, Pelkmans L.Image-based transcriptomics in thousands of single human cells at singlemolecule resolution[J]. Nat Methods,2013,10(11):1127-1133.
|
| [16] |
Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing[J]. Nature,2011,472(7341):90-94.
|
| [17] |
Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing[J]. Nature,2014,512(7513):155-160.
|
| [18] |
Zhang J, Fujimoto J, Wedge DC, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing[J]. Science, 2014, 346 (6206):256-259.
|
| [19] |
Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells[J]. Cancer Res,2005,65(12):4993-4997.
|
| [20] |
Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer[J]. Nat Biotechnol,2014,32(5):479-484.
|
| [21] |
Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients[J]. Proc Natl Acad Sci U S A,2013,110(52):21083-21088.
|
| [22] |
Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J]. Science,2014,345(6193):216-220.
|
| [23] |
吴一龙,秦叔逵,马军. 中国临床肿瘤学进展2014 [M]. 北京: 人民卫生出版社,2014:193.
|
| [24] |
Onstenk W, Gratama JW, Foekens JA, et al. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics[J]. Cancer Treat Rev,2013,39(7):691-700.
|
| [25] |
Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients[J].Cancer Cell,2013,23(5):573-581.
|
| [26] |
Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer[J].Clin Cancer Res,2012,18(20):5701-5710.
|
| [27] |
Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay[J]. Nat Biotechnol,2013,31(6):539-544.
|
| [28] |
Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis[J]. Sci Transl Med,2013,5(180):180ra148.
|
| [29] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J].N Engl J Med,2013,368(13):1199-1209.
|
| [30] |
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science,2013,339(6119):580-584.
|
| [31] |
Aceto N,Bardia A,Miyamoto DT,et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis[J]. Cell,2014,158(5):1110-1122.
|
| [32] |
Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis[J]. J Natl Cancer Inst, 2010,102(9):627-637.
|
| [33] |
Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution[J].Clin Cancer Res,2008,14(2):370-378.
|
| [34] |
Klein CA, Schmidt-Kittler O, Schardt JA, et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells[J]. Proc Natl Acad Sci U S A,1999,96(8):4494-4499.
|
| [35] |
Sun YF. Circulating tumor cells en route: their distinct molecular characteristics and clinical significance at different vascular sites in patients with localized hepatocellular carcinoma[EB/OL]. [2014-09-20]. http:/ /reg.csco.org.cn/reg2014/htm/201409201p.pdf.
|
| [36] |
André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial(SAFIR01/UNICANCER)[J]. Lancet Oncol,2014,15(3):267-274.
|
| [37] |
Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia[J]. Cell,2013,152(4):714-726.
|
| [38] |
Junttila MR, De Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response[J]. Nature,2013,501(7467):346-354.
|
| [39] |
Johnson GL, Stuhlmiller TJ, Angus SP, et al. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer[J]. Clin Cancer Res,2014,20(10):2516-2522.
|
| [40] |
Sounni NE, Cimino J, Blacher S, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal[J]. Cell Metab,2014,20(2):280-294.
|
| [41] |
Zhang W,Sun HC,Wang WQ,et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice[J].Gastroenterology,2012,143(6):1641-1649.
|
| [42] |
Gravitz L. Therapy: This time it’ s personal[J]. Nature,2014,509(7502): S52-54.
|